AbCellera’s Financial Results and Business Update
AbCellera Biologics Inc. (ticker: ABCL) recently discussed their Q2 2024 financial results and provided a business update, focusing on the advancement of their internal pipeline and strategic partnerships. The company plans to submit Clinical Trial Applications (CTAs) for two of their programs, ABCL635 and ABCL575, in Q2 2025.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
